Arena Pharmaceuticals (ARNA) Tops Q2 Loss Views by 1c
Arena Pharmaceuticals (Nasdaq: ARNA) reports Q2 loss of $0.28, cents better than the analyst estimate of ($0.29). Revenue for the quarter was $2.46 million, which compares to the estimate of $2.97 million.
You May Also Be Interested In
- Aoxing Pharmaceutical (AXN) to Delay 10-K Filing
- DTE Energy (DTE) Increases 2016 Operating Earnings Guidance
- BlackBerry (BBRY) Tops Q2 EPS by 5c; Will End Internal Hardware Development; Boosts FY17 Outlook
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!